This is an open-label single-arm study, that will provide continued access to study drug to participants who completed their participation in parent studies sponsored by Gilead Sciences US, which include; GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, GS-US-216-0128, or CO-US-380-5578.
Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) will be provided for participants rolling-over from GS-US-380-1474- or CO-US-380-5578. Emtricitabine/Tenofovir Alafenamide (F/TAF) will be provided by Gilead Sciences for participants rolling-over from GS-US-311-1269.
Expected impact: Continued access to efficacious ART before access is possible through national local supply chain systems.
